Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study

被引：15
|
作者：
Zhao, Qian [1 ]
Zhu, Zicong [1 ]
Fu, Qiaoyu [1 ]
Shih, Yanting [1 ]
Wu, Dan [1 ]
Chen, Lihong [1 ]
Zheng, Jie [1 ]
Cao, Hua [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Dermatol, 197 Ruijin 2nd Rd, Shanghai, Peoples R China
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 06期
基金：
中国国家自然科学基金;
关键词：
autoimmune skin disease; baricitinib; CDASI; dermatomyositis; JAK inhibitors;
D O I：
10.1016/j.jaad.2022.08.025
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：1374 / 1376
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study
    Fernandez, Anthony P.
    Gallop, Josh
    Polly, Samantha
    Khanna, Urmi
    [J]. RHEUMATOLOGY, 2023,
  • [2] Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study
    Brumfiel, Caitlin M.
    Patel, Meera H.
    Severson, Kevin J.
    Zhang, Nan
    Li, Xing
    Quillen, Jaxon K.
    Zunich, Samantha M.
    Branch, Emily L.
    Nelson, Steven A.
    Pittelkow, Mark R.
    Mangold, Aaron R.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : 2109 - +
  • [3] An open-label trial of rituximab in the treatment of patients with dermatomyositis
    Chung, L
    Fiorentino, D
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB77 - AB77
  • [4] Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
    Koster, Matthew
    Crowson, Cynthia
    Giblon, Rachel
    Duarte-Garcia, Ali
    Jaquith, Jane
    Weyand, Cornelia M.
    Warrington, Kenneth
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2920 - 2923
  • [5] Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis
    Danieli, Maria Giovanna
    Moretti, Romina
    Gambini, Simona
    Paolini, Luca
    Gabrielli, Armando
    [J]. CLINICAL RHEUMATOLOGY, 2014, 33 (04) : 531 - 536
  • [6] Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis
    Maria Giovanna Danieli
    Romina Moretti
    Simona Gambini
    Luca Paolini
    Armando Gabrielli
    [J]. Clinical Rheumatology, 2014, 33 : 531 - 536
  • [7] Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
    Koster, Matthew J.
    Crowson, Cynthia S.
    Giblon, Rachel E.
    Jaquith, Jane M.
    Duarte-Garcia, Ali
    Matteson, Eric L.
    Weyand, Cornelia M.
    Warrington, Kenneth J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 861 - 867
  • [8] Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
    Fernandez, Anthony
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [9] Preliminary results of an open-label study assessing efficacy and safety of repository corticotropin injection for treatment of refractory cutaneous manifestations of dermatomyositis
    Fernandez, Anthony P.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB52 - AB52
  • [10] Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis
    Delvino, Paolo
    Bartoletti, Alice
    Monti, Sara
    Biglia, Alessandro
    Montecucco, Carlomaurizio
    Carducci, Mauro
    Ripamonti, Giorgio
    Cavagna, Lorenzo
    [J]. RHEUMATOLOGY, 2020, 59 (12) : E125 - E127
12345